Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Mid-range Performer

2579.1000 7.10 (0.28%)

NSE Sep 12, 2025 15:31 PM

Volume: 58,267

Ajanta Pharma Ltd.

04 Nov 2020

2579.10

0.28%

Ajanta Pharma (BUY): Exceptional Q2 beat; H2 momentum to moderate

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) posted Q2 revenue/EBITDA growth of 11%/54% YoY to Rs 7.2bn/Rs 2.7bn.

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr